168 related articles for article (PubMed ID: 19066339)
1. Cardiac-targeted expression of soluble fas attenuates doxorubicin-induced cardiotoxicity in mice.
Niu J; Azfer A; Wang K; Wang X; Kolattukudy PE
J Pharmacol Exp Ther; 2009 Mar; 328(3):740-8. PubMed ID: 19066339
[TBL] [Abstract][Full Text] [Related]
2. Protection against lipopolysaccharide-induced myocardial dysfunction in mice by cardiac-specific expression of soluble Fas.
Niu J; Azfer A; Kolattukudy PE
J Mol Cell Cardiol; 2008 Jan; 44(1):160-9. PubMed ID: 17996250
[TBL] [Abstract][Full Text] [Related]
3. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro.
Mukhopadhyay P; Rajesh M; Bátkai S; Kashiwaya Y; Haskó G; Liaudet L; Szabó C; Pacher P
Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1466-83. PubMed ID: 19286953
[TBL] [Abstract][Full Text] [Related]
4. Sirt6 protects cardiomyocytes against doxorubicin-induced cardiotoxicity by inhibiting P53/Fas-dependent cell death and augmenting endogenous antioxidant defense mechanisms.
Wu S; Lan J; Li L; Wang X; Tong M; Fu L; Zhang Y; Xu J; Chen X; Chen H; Li R; Wu Y; Xin J; Yan X; Li H; Xue K; Li X; Zhuo C; Jiang W
Cell Biol Toxicol; 2023 Feb; 39(1):237-258. PubMed ID: 34713381
[TBL] [Abstract][Full Text] [Related]
5. Anti-Fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis.
Miyata S; Takemura G; Kosai K; Takahashi T; Esaki M; Li L; Kanamori H; Maruyama R; Goto K; Tsujimoto A; Takeyama T; Kawaguchi T; Ohno T; Nishigaki K; Fujiwara T; Fujiwara H; Minatoguchi S
Am J Pathol; 2010 Feb; 176(2):687-98. PubMed ID: 20035047
[TBL] [Abstract][Full Text] [Related]
6. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction.
Pacher P; Liaudet L; Bai P; Mabley JG; Kaminski PM; Virág L; Deb A; Szabó E; Ungvári Z; Wolin MS; Groves JT; Szabó C
Circulation; 2003 Feb; 107(6):896-904. PubMed ID: 12591762
[TBL] [Abstract][Full Text] [Related]
7. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice.
Shizukuda Y; Matoba S; Mian OY; Nguyen T; Hwang PM
Mol Cell Biochem; 2005 May; 273(1-2):25-32. PubMed ID: 16013437
[TBL] [Abstract][Full Text] [Related]
8. Matricellular protein CCN1 mediates doxorubicin-induced cardiomyopathy in mice.
Hsu PL; Mo FE
Oncotarget; 2016 Jun; 7(24):36698-36710. PubMed ID: 27167338
[TBL] [Abstract][Full Text] [Related]
9. Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation.
Martin LJ; Chen K; Liu Z
J Neurosci; 2005 Jul; 25(27):6449-59. PubMed ID: 16000635
[TBL] [Abstract][Full Text] [Related]
10. Targeted cardiac expression of soluble Fas prevents the development of heart failure in mice with cardiac-specific expression of MCP-1.
Niu J; Azfer A; Deucher MF; Goldschmidt-Clermont PJ; Kolattukudy PE
J Mol Cell Cardiol; 2006 Jun; 40(6):810-20. PubMed ID: 16678847
[TBL] [Abstract][Full Text] [Related]
11. Acylated Ghrelin Protects the Hearts of Rats from Doxorubicin-Induced Fas/FasL Apoptosis by Stimulating SERCA2a Mediated by Activation of PKA and Akt.
Shati AA; Dallak M
Cardiovasc Toxicol; 2019 Dec; 19(6):529-547. PubMed ID: 31093930
[TBL] [Abstract][Full Text] [Related]
12. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin.
Neilan TG; Blake SL; Ichinose F; Raher MJ; Buys ES; Jassal DS; Furutani E; Perez-Sanz TM; Graveline A; Janssens SP; Picard MH; Scherrer-Crosbie M; Bloch KD
Circulation; 2007 Jul; 116(5):506-14. PubMed ID: 17638931
[TBL] [Abstract][Full Text] [Related]
13. Docosahexaenoic Acid Attenuates Doxorubicin-induced Cytotoxicity and Inflammation by Suppressing NF-κB/iNOS/NO Signaling Pathway Activation in H9C2 Cardiac Cells.
Wang ZQ; Chen MT; Zhang R; Zhang Y; Li W; Li YG
J Cardiovasc Pharmacol; 2016 Apr; 67(4):283-9. PubMed ID: 26657886
[TBL] [Abstract][Full Text] [Related]
14. Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice.
Zhang W; Deng J; Sunkara M; Morris AJ; Wang C; St Clair D; Vore M
J Pharmacol Exp Ther; 2015 Nov; 355(2):280-7. PubMed ID: 26354995
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X
Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254
[TBL] [Abstract][Full Text] [Related]
16. Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.
Yokoyama C; Aoyama T; Ido T; Kakino A; Shiraki T; Tanaka T; Nishigaki K; Hasegawa A; Fujita Y; Sawamura T; Minatoguchi S
PLoS One; 2016; 11(5):e0154994. PubMed ID: 27195769
[TBL] [Abstract][Full Text] [Related]
17. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment.
Shuai Y; Guo JB; Peng SQ; Zhang LS; Guo J; Han G; Dong YS
Toxicol Lett; 2007 Apr; 170(1):66-74. PubMed ID: 17382496
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
Sun X; Zhou Z; Kang YJ
Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
[TBL] [Abstract][Full Text] [Related]
19. Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells.
Guo R; Wu K; Chen J; Mo L; Hua X; Zheng D; Chen P; Chen G; Xu W; Feng J
Cell Physiol Biochem; 2013; 32(6):1668-80. PubMed ID: 24356372
[TBL] [Abstract][Full Text] [Related]
20. Serine mutations in overexpressed Hsp27 abrogate the protection against doxorubicin-induced p53-dependent cardiac apoptosis in mice.
Kanagasabai R; Karthikeyan K; Zweier JL; Ilangovan G
Am J Physiol Heart Circ Physiol; 2021 Nov; 321(5):H963-H975. PubMed ID: 34477462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
